Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 2;12:123. doi: 10.1186/s13195-020-00696-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 3 — Aβ40 in different diagnoses; representation in percentile; AD odds ratio, age, and p-tau (181) distribution. The Montpellier, Paris, and SPIN-Barcelona cohorts displayed a large range of pathological samples from patients with Alzheimer’s disease (AD), mild cognitive impairment (MCI), frontotemporal dementia (FTD), Control (subjective cognitive impairment), and the other neurological diseases (Other) (see also Sup-Figure 3). Mean-centered Aβ40 values in these cohorts were combined and compared in the different clinical groups confirming the significant increase of the peptides in AD (a). The four cohorts (Montpellier 1 (Mtp-1), Montpellier 2 (Mtp-2), Paris, SPIN-Barcelona) have been sorted in four classes based on their Aβ40 percentile values as follows: p25, < 25th percentile; p25–50, 25th–50th percentile; p50–75, 50th–75th percentile; and p75, > 75th. The odds ratio for AD (b), the age of the patients (c), and the concentration of CSF p-tau (181) (d) were then plotted in each percentile class. Significant differences between classes are indicated